There are no early stage diagnostics for ovarian cancer and by the time they are discovered, they may not respond to standard cancer treatments. But a new research from A*STAR's Institute of Medical Biology (IMB) and the Bioinformatics Institute (BII) have found new clues to early detection and personalized treatments of ovarian cancer, thus offering hope to millions of women who might be susceptible to it. Their findings were published online in Nature Cell Biology in July…
This new class of drugs unleashes the body's immune system to fight tumors. This seems to solve a century-old mystery of how cancerous cells manage to evade the body's immune system. The drug which Merck will sell under the name of Keytruda was approved by patients with advanced melanoma who have exhausted other therapies.
Community
Condition